relative to increasing transparency in the 340B Drug Pricing Program.

Introduced

In Committee

Floor

Crossed Over

Passed

Enacted

Overview Bill text 1 History 7 Sponsors 9

Mar 5, 2026 · Senate

Refer to Interim Study, MA, VV; 03/05/2026; SJ 5

Feb 19, 2026 · Senate

SB 477 was Removed from the Consent Calendar; 02/19/2026; SJ 4

Feb 19, 2026 · Senate

Special Order to the Next Session, Without Objection, MA; 02/19/2026; SJ 4

Feb 19, 2026 · Senate

Committee Report: Referred to Interim Study, 03/05/2026, Vote 5-0; SC 8

Feb 12, 2026 · Senate

Committee Report: Referred to Interim Study, 02/19/2026; Vote 5-0; CC; SC 6

Jan 12, 2026 · Senate

Hearing: 01/21/2026, Room 100, SH, 01:30 pm; SC 2

Nov 21, 2025 · Senate

Introduced 01/07/2026 and Referred to Health and Human Services; SJ 1

PASSAGE PROBABILITY

18.2% Unlikely

Why this number

Stage base In Committee — base rate 27%, measured from NH's completed sessions
Momentum -1 47/100 from the pace of recorded action
Time since last action -22 219 days quiet
Cosponsors +10 8 signed on
Sponsor influence +4 92/100

A transparent scoring model over stage, momentum, recency, sponsorship and recorded votes — not a trained predictor. Treat it as a way to rank attention, not as a forecast.